search
Back to results

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

Primary Purpose

Asymptomatic Hyperuricemia

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
verum acupuncture
health education
sham acupuncture
Sponsored by
Tongji Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asymptomatic Hyperuricemia focused on measuring Manual Acupuncture, Asymptomatic Hyperuricemia, Serum Uric Acid, Efficacy, Safety

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed as hyperuricemia; and
  • Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and
  • Without history of gouty arthritis; and
  • Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and
  • 18.5kg/m2≤BMI≤30.0kg/ m2; and
  • Able to signing a informed consent.

Exclusion Criteria:

  • Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and
  • Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and
  • Patients have history of gouty arthritis; and
  • Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and
  • Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and
  • Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and
  • Pregnant women; and
  • Unwilling to accept acupuncture treatment; and
  • Illiterate, or patients unable to sign informed consent; and
  • The completion rate of baseline screening data is ≤80%.

Sites / Locations

  • Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Verum acupuncture (VA)

Sham acupuncture (SA)

Arm Description

Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.

Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.

Outcomes

Primary Outcome Measures

Changes in the mean level of serum uric acid from baseline.
The changes in the mean level of serum uric acid at 8 weeks after randomization compared to baseline

Secondary Outcome Measures

Changes in the mean level of serum uric acid from baseline.
The changes in the mean level of serum uric acid at 4, 12, 16, 20 weeks after randomization compared to baseline
Effective rate of patients with serum uric acid ≤ 6.0 mg/dL
The ratio of patients with serum uric acid ≤ 6.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization
Effective rate of patients with serum uric acid ≤ 7.0 mg/dL
The ratio of patients with serum uric acid ≤ 7.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization
The proportion of patients with acute gouty arthritis
The proportion of patients with acute gouty arthritis per 4-week cycle after randomization.
Changes in body weight of patients
Changes in body weight of patients at 4, 8, 12, 16, and 20 weeks after randomization.
Changes in the dose of intake of acute medication.
The changes in the dose of intake of acute medication per 4-week cycle after randomization.
Arrival of qi assessment
The Chinese Version of the Massachusetts General Hospital Acupuncture Sensation Scale Acupuncture sensations will be measured by the Massachusetts General Hospital (MGH) Acupuncture Sensation Scale (MASS)
Safety evaluation
Adverse events during the acupuncture process

Full Information

First Posted
June 1, 2022
Last Updated
March 12, 2023
Sponsor
Tongji Hospital
Collaborators
Wuhan Integrated Traditional Chinese and Western Medicine Hospital, Xianning Central Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05406830
Brief Title
Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia
Official Title
Evaluating the Efficacy of Acupuncture for Patients With Asymptomatic Hyperuricemia (HUA): A Multicenter Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 13, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tongji Hospital
Collaborators
Wuhan Integrated Traditional Chinese and Western Medicine Hospital, Xianning Central Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.
Detailed Description
This is a multicentre, stratified, randomized, sham-controlled clinical trial. 180 eligible participants will be randomly allocated into verum acupuncture group or sham acupuncture group, in a 1:1 ratio. The verum acupuncture group will receive 16 sessions of manual acupuncture treatments over an eight-week period, while the sham acupuncture group will receive sham acupuncture treatments with non-penetrating needling. Health education will be provided to participants in the two groups. The primary outcomes will be the changes in the mean levels of serum uric acid 8 weeks after randomization. The secondary outcomes will be the changes in the mean levels of serum uric acid 4, 12, 16, and 20 weeks after randomization. Other secondary outcomes included effective rates, the proportion of patients with acute gouty arthritis, changes in body weight and BMI, safety evaluation and deqi evaluation. The central randomization and data collection will be conducted by an electronic data management system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asymptomatic Hyperuricemia
Keywords
Manual Acupuncture, Asymptomatic Hyperuricemia, Serum Uric Acid, Efficacy, Safety

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Verum acupuncture (VA)
Arm Type
Experimental
Arm Description
Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Arm Title
Sham acupuncture (SA)
Arm Type
Sham Comparator
Arm Description
Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Intervention Type
Device
Intervention Name(s)
verum acupuncture
Intervention Description
The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
Intervention Type
Behavioral
Intervention Name(s)
health education
Intervention Description
According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
Intervention Type
Device
Intervention Name(s)
sham acupuncture
Intervention Description
We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
Primary Outcome Measure Information:
Title
Changes in the mean level of serum uric acid from baseline.
Description
The changes in the mean level of serum uric acid at 8 weeks after randomization compared to baseline
Time Frame
At baseline, and at 8 weeks after randomization.
Secondary Outcome Measure Information:
Title
Changes in the mean level of serum uric acid from baseline.
Description
The changes in the mean level of serum uric acid at 4, 12, 16, 20 weeks after randomization compared to baseline
Time Frame
At baseline, at 4, 12, 16, and 20 weeks after randomization.
Title
Effective rate of patients with serum uric acid ≤ 6.0 mg/dL
Description
The ratio of patients with serum uric acid ≤ 6.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization
Time Frame
4, 8, 12, 16 and 20 weeks after randomization
Title
Effective rate of patients with serum uric acid ≤ 7.0 mg/dL
Description
The ratio of patients with serum uric acid ≤ 7.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization
Time Frame
4, 8, 12, 16 and 20 weeks after randomization
Title
The proportion of patients with acute gouty arthritis
Description
The proportion of patients with acute gouty arthritis per 4-week cycle after randomization.
Time Frame
Weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.
Title
Changes in body weight of patients
Description
Changes in body weight of patients at 4, 8, 12, 16, and 20 weeks after randomization.
Time Frame
4, 8, 12, 16 and 20 weeks after randomization
Title
Changes in the dose of intake of acute medication.
Description
The changes in the dose of intake of acute medication per 4-week cycle after randomization.
Time Frame
Weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.
Title
Arrival of qi assessment
Description
The Chinese Version of the Massachusetts General Hospital Acupuncture Sensation Scale Acupuncture sensations will be measured by the Massachusetts General Hospital (MGH) Acupuncture Sensation Scale (MASS)
Time Frame
Immediately following each session of acupuncture treatment.
Title
Safety evaluation
Description
Adverse events during the acupuncture process
Time Frame
Immediately following each session of acupuncture treatment.
Other Pre-specified Outcome Measures:
Title
60-item NEO Personality Inventory-Short Form (NEO-FFI)
Time Frame
At baseline only once.
Title
Chinese medicine constitution classification
Time Frame
At baseline only once.
Title
Acupuncture Expectancy Scale
Time Frame
At baseline only once.
Title
Change in Beck Anxiety Inventory(BAI).
Time Frame
At baseline only once.
Title
Change in Beck Depression Inventory II(BDI- II).
Time Frame
At baseline only once.
Title
Change in Patient-Doctor Relationship Questionnaire(PDRQ-9) .
Time Frame
At baseline only once.
Title
Change in Difficult Doctor-Patient Relationship Questionnaire(DDPRQ-10).
Time Frame
At baseline only once.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed as hyperuricemia; and Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and Without history of gouty arthritis; and Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and 18.5kg/m2≤BMI≤30.0kg/ m2; and Able to signing a informed consent. Exclusion Criteria: Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and Patients have history of gouty arthritis; and Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and Pregnant women; and Unwilling to accept acupuncture treatment; and Illiterate, or patients unable to sign informed consent; and The completion rate of baseline screening data is ≤80%.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lingling Yu, PhD
Phone
86-13545862185
Email
527679774@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shenghao Tu, PhD
Organizational Affiliation
Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,430030, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
玲玲 余
Phone
+8613545862185
Email
527679774@qq.com

12. IPD Sharing Statement

Learn more about this trial

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

We'll reach out to this number within 24 hrs